ABSTRACT. PolyLactic and Glycolic Acid nanoparticles (PLGA-NPs
INTRODUCTION
Nanotechnology is under intense scrutiny in the design of new medical protocols, as a significant improvement of diagnoses and therapy 1 , in particular of cancer and cardiovascular diseases, is expected from the application of nanosized drug delivery systems 2 . In this contest, liposomes, solid-lipid nanoparticles, and biodegradable polymeric nanoparticles are the most widely investigated systems. Poly (D, L-lactide-co-glicolide) (PLGA) has attracted great attention in the design of nanosized delivery systems because of its excellent biocompatibility and biodegradability, associated to the presence of ester linkages that undergo slow hydrolysis in aqueous system 3 . The removal of nanosized drug carriers from the body, due to their hydrophobic nature, by the Mononuclear Phagocyte System is a major obstacle that hinders the application of these drug delivery systems 4 . Therefore surface modification and coating of PLGA nanoparticles is the subject of studies aimed at prolonging their circulation lifetime. The most commonly used strategy to obtain stealth nanoparticles is based on the use of PEG and it has led to the development of several products that are currently in clinical use 5 . However, the recent observation of anti-PEG immunological response 6 has motivated a renewed interest towards the research for alternative strategies. Among possible surface modification of PLGA nanoparticles, serum albumin has received some attention due to its relatively small size, hydrophilic surface and accumulation in leaky vasculature of tumours through passive targeting [7] [8] [9] . PLGA nanoparticles coated with serum albumin showed an improved stability and when loaded with the anti-tumoral paclitaxel drug, a more efficient delivery to tumour cells. Herein we report results concerning the use of Ferritin as alternative protein coating for PLGA surface. In addition to act as a hydrophilic cover, Ferritin may endow the nanoparticle with a potential targeting capability thus improving the uptake from the tumour cells through specific ferritin receptors.
Ferritin is the main iron storage protein and is composed of 24 subunits of heavy (H)-or light (L)-chain polypeptides that are present at different ratios in various organs to form a cage architecture of 12 nm in external diameter, with an inner cavity of 8 nm 10 . Ferritin functions are traditionally associated with intracellular iron storage but additional functions related to iron delivery based on a transferrin-independent mechanism to different target organs (such as brain, liver and spleen) have been recently discovered and investigated 11 . The involved receptors belong to scavenger receptor class A member 5 (SCARA5) 12-14 for L-ferritin and to TIM-2 15 and TfR-1 16, 17 for H-ferritin, in mice and human, respectively. Based on evidence attained from both 4 epidemiological and molecular studies, new insights are linking the presence of excess iron and altered iron metabolism to cancer as a consequence of the rapid cell proliferation 18 . It is well known that, many cancer cells reprogram iron metabolism in ways that result in net iron influx 19 .
This occurs through the up-regulation of the expression of proteins that are involved in iron uptake (i.e. TfR1, SCARA5) and the decreased expression of iron efflux proteins, such as ferroportin. The relationship between ferritin and cancer is well supported by studies showing an increase of the total ferritin (rich in L-chains) in the blood serum 20 . For example, in breast cancer patients, it was found a correlation with ferritin increase and the stage of the disease, as the high serum concentration of the protein is associated with the release within the breast tumor microenvironment 21 . Accordingly, breast tumor lysates also show elevated levels of L-ferritin, the predominant subunit observed in serum, and this increase correlates with advanced histological grade and poor outcome 22, 23 . There are many examples in the literature exploiting ferritin for the delivery of water soluble drugs and imaging agents loaded in its inner aqueous cavity [24] [25] [26] [27] . In this context, we have previously reported that native horse spleen Ferritin (composed by 85% and 15% L and H chains, respectively) is selectively taken-up by the human breast cancer cell line MCF7 through SCARA5 receptors 28 .
On this basis herein we propose the use of ferritin as simultaneous targeting and coating agent for PLGA nanoparticles, able to deliver selectively paclitaxel (PTX), a cytostatic compound with very low water solubility, to breast cancer (MCF-7 cells). Horse spleen ferritin has been covalently conjugated to the external surface of PLGA nanoparticles exploiting NHS activated carboxylic groups ( Figure 1A ). Moreover, PLGA nanoparticles have been loaded with a Gd based MRI imaging agent (Gd-DOTAMA, Figure 1B ), in order to monitor their distribution. The performance of ferritin functionalized PLGA nanoparticles has been compared with the corresponding albumin coated ones as well as with unfunctionalized particles.
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RESULTS AND DISCUSSION
Preparation of PLGA nanoparticles (PLGA-NPs)
PLGA is one of the most attractive biodegradable and biocompatible polymer that has been used in a number of applications, ranging from drug delivery to tissue engineering 29 . PLGA nanoparticles are characterized by a hydrophobic core that enables entrapping water insoluble hydrophobic molecules. PLGA-NPs were obtained by the o/w emulsion solvent extraction method. The organic phase was prepared by dissolving PLGA or PLGA-NHS and Gd-DOTAMA complex in chloroform 30 . The water phase was a poly vinyl alcohol (PVA) aqueous solution. PVA is the most commonly used emulsifier for the preparation of PLGA-based NPs because it yields particles that are relatively uniform, small sized, and easy to be re-dispersed in water 31 . The organic phase was added to the aqueous phase, and then the resulting mixture has been extensively sonicated. The nanoparticles were obtained by the slow organic solvent evaporation of the o/w emulsion. Then, ferritin (Horse Spleen Ferritin) or bovine serum albumin (BSA) were covalently conjugated to PLGA-NHS nanoparticles exploiting the reaction of PLGA-NHS with the amine groups present on the proteins external surface [32] [33] [34] . Before conjugation Ferritin was purified by gel filtration chromatography to eliminate high molecular weight aggregates whereas BSA was used without further purification. The reaction was carried out overnight, at room temperature, under magnetic stirring. Pure PLGA-Ferr and PLGA-BSA have been obtained after size exclusion chromatography (see supporting Information, Figure S1 ).
Control nanoparticles (PLGA-CTRL), without protein coating, were synthesized following the same synthetic protocol using the commercially available PLGA with unconjugated carboxylic groups. As reported in Table 1 Ferritin and BSA. The obtained solutions were purified by gel filtration using the same protocol.
In the solutions of purified nanoparticles the protein concentrations was in both cases under the detection limit (0.034mg/ml). The low absorption is the consequence of the lower albumin (BSA) concentration incubated (2 mg/ml) and the negative Z-potential of PLGA-CTRL (-3.9±1.5). The number of GdDOTAMA loaded in one nanoparticle (ca. 1x10 5 ) is of the same order of those reported for liposomes or other nanoparticles embedded with contrast agents in their interior and not only on their surface 37, 38 . Figure 2A 9
Magnetic Resonance Imaging (MRI)
In order to assess whether Gd-labelled PLGA-NPs can generate a sufficient MRI contrast for targeted cells MCF7 and MDA-MB-231, T 1 -weighted MR images were acquired on cellular pellets obtained upon incubation with PLGA-Ferr and PLGA-BSA (50 µM of Gd), respectively. Loading of Paclitaxel in PLGA-NPs. 
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In order to design a "theranostic" system containing both imaging and therapeutic agents, paclitaxel (PTX) has been added to the previously described PLGA-NPs. Paclitaxel is a drug largely used in the treatment for various types of cancer, including ovarian cancer, breast cancer, non-small cell lung cancer and Kaposi's sarcoma 39 . PTX is characterized by a low solubility in water and it is administered to patients in a micellar formulation based on macrogolglycerol ricinoleate dissolved in ethanol 40, 41 . The preparation of PLGA-PTX nanoparticles was performed using the same procedure described above. PTX was dissolved in chloroform together with PLGA or PLGA-NHS and Gd-DOTAMA at an initial PTX amount corresponding to 10% w/w (with respect to PLGA). Then pre-formed PLGA nanoparticles were conjugated with the protein (Ferritin or BSA). The PTX encapsulation yields, determined by HPLC, were 6.88±0.98, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
Figure 4: In vitro drug release from PLGA-PTX-CTRL, PLGA-PTX-Ferr and PLGA-PTX-BSA evaluated at different time (6, 24, 48h) under dialysis in PBS at 37°C, pH=7.4. Graphs show the mean ± SD of % PTX release obtained by 3 independent experiments.
PTX release from nanoparticles depends on drug diffusion at the PLGA surface that, in turn, is affected by "bulk" erosion or swelling 42 . The PTX release behavior from the herein developed nanoparticles exhibited a biphasic pattern characterized by an initial rapid release during the first 24 h, followed by a slower and continuous release. The high initial burst release can be attributed to the dissolution of PTX physically adhered at the surface or located at the first layers of the solid nanoparticles 40 . It is likely that the presence of Ferritin or BSA on the surface of PLGANPs slowed down this burst release compared to PLGA-PTX-CTRL Furthermore, the presence of protein on the outside layer of NPs could slowdown diffusion of hydrophobic PTX to the outside medium, making release slower compared to NP without protein coating. Also, the increasing diffusional distance for PTX molecule may delay the drug release from the core of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12
Toxicity test of PLGA-PTX nanoparticles
Viability assays were performed on MCF-7, as they showed a good capability to take-up PLGA-PTX-Ferr nanoparticles. Cells were incubated in the presence of PLGA-PTX_Ferr, PLGA-PTX-BSA, PLGA-PTX-CTRL and a commercially available Paclitaxel formulation administered to human patients (Paclitaxel Kabi) at increasing concentrations for 6h and 24h ( Figure 5A ,B). The range of concentrations of PTX corresponds to plasma levels of the drug achievable in humans 46 .
As mentioned above, Paclitaxel Kabi is a water soluble paclitaxel formulation containing macroglycol ricinolate. In agreement with that previously reported by Esfandyari-Manesh and coworkers 7 , we found that the toxicity, herein evaluated by MTT assay, of PLGA coated with BSA and loaded with PTX (PLGA-PTX-BSA) is significantly higher than the one observed for the commercially available Paclitaxel Kabi and for the PTX loaded PLGA-PTX-CTRL. The observed behavior may be accounted for the presence of gp60 (albondin) receptor and caveolar transport as both systems are involved in the transendothelial cell transport of albumin 7 . The data reported in Figure 5 show that the cytotoxicity is further enhanced by using PLGA coated with The low toxicity of the commercial drug is very likely due to the short treatment time, only 6h, which does not lead to enough internalized drug to have detectable cytotoxic effect. In fact, several experiments are reported in the literature where the therapeutic treatment is continued for more than 24 hours 41 . While the percent viability of MCF-7 after 24h of incubation at 20µM of PTX with PLGA-PTX-Ferr, PLGA-PTX-CTRL, PLGA-PTX-BSA, and Paclitaxel Kabi were 29%, 45%, 63% and 72% ( Figure 5B ). The cytotoxicity of nanoparticles not loaded with paclitaxel was evaluated (see supplementary information, Figure S4 ) and it was less than 10%
for all the PLGA-NPs after 6 and 24h incubation. Nanoparticles with or without PTX were incubated with cells at the same Gd concentration. In order to prove the selective toxic effect of PLGA-PTX-Ferr for tumor cells a comparative cytotoxicity study was done on the human mammary non-tumorigenic epithelial cell line MCF-10A using the same protocol described above. Figure 6 shows clearly that PLGA-PTX-Ferr are significantly more toxic for tumor cells (MCF7) than healthy MCF-10A after 6 and 24h incubation. From these results one draws the conclusion that the specific uptake of PLGA-PTX-Ferr by breast cancer cells (MCF7) allows to increase the therapeutic output of PTX thus overcoming some limitation currently encountered in the clinical use of this drug. Indeed, despite of a wide spectrum of antitumor activity of PTX, its 
CONCLUSIONS
In this work it has been shown that the novel drug delivery system based on hydrophobic PLGA nanoparticles decorated with Ferritin has many advantages with respect non decorated particles. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 15 reaching the target. Finally, the versatility of the PLGA nanoparticles permits the combination of therapy and diagnosis by entrapping MRI contrast agents inside the PLGA-NPs hydrophobic core, in a single drug delivery system.
EXPERIMENTAL PROCEDURES Materials
Poly ( 
Synthesis of N-hydroxysuccinimide activated PLGA (PLGA-NHS).
PLGA polymer (100 mg, 0.0025mmol) was dissolved in CH 3 CN (1 ml). EDC (20 mg, 0.1 mmol) and NHS (10 mg, 0.09 mmol), both dissolved in CH 3 CN (0.5 ml) were subsequently added, to PLGA solution. The reaction was left to stir at room temperature for 12 h. The product was precipitated in diethyl ether and washed several times with diethyl ether/methanol (1:1) and dried under vacuum. The 13 C-NMR (600 MHz, CDCl3) was used to assess the formation of the NHS ester ( Figure S2 in Supporting Information). The disappearance of the carboxyl groups at 174.2 and 171.8 ppm, corresponding to the PLGA carboxylic acid groups, proved the formation of NHS ester. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 where m is the NP weight, D is the number based on mean NP diameter determined by dynamic light scattering (DLS) and ρ is the NP weight per volume unit (density), estimated to be 1.1 g/cm 3 based on the polymer density 46 . The NP weight (m) was indirectly determined by the GdDOTAMA concentration considering than about 8 mg of GdDOTAMA are loaded into 100 mg of PLGA nanoparticles as estimated by three independent PLGA-NPs preparations, purified by dialysis without centrifugation that causes nanoparticles aggregation and loss.
Preparation of PLGA-NPs
Cell lines
MDA-MB-231 cells were cultured in DMEM medium containing 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin, 100 U/ml streptomycin, 0.01% and 4 mM L-glutamine. MCF-7 cells were cultured in EMEM medium containing 10% (v/v) FBS, 100 U/ml penicillin and streptomycin, 1% (v/v) non-essential amino acid, 1 mM sodium pyruvate, 2 mM L-glutamine, and 0.01 mg/ml insulin. The MCF 10A cells were cultured in Dulbecco's modified Eagle's medium and Ham's F12 medium supplemented with 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone and 5% of horse serum. Cells were incubated at 37°C under a humidified atmosphere of 5% CO 2 . These cell lines were tested for mycoplasma (MycoAlert™ PLUS Mycoplasma Detection Kit, Lonza). (proportional to the cell number) was determined from cell lysates by the Bradford assay.
Uptake experiments
MRI
All the MR images were acquired on a Bruker Avance 300 spectrometer (7T) equipped with a Micro 2.5 microimaging probe (Bruker BioSpin, Ettlingen, Germany).Glass capillaries containing about 2 × 10 6 cells were placed in an agar phantom and MR imaging was performed by using a standard T 1 -weighted multislice spin-echo sequence (TR/TE/ NEX = 250/3.7/8, FOV = 1.2 cm, MTX= 128x128, NEX = number of excitations; FOV = field of view). The T 1 relaxation times were calculated using a standard saturation recovery spin echo.
Preparation and characterization of PTX loaded PLGA-NPs
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